Analysts: Facebook Has Upside from Instagram and 3 Other Research Notes to Read Through
Facebook (NASDAQ:FB): Canaccord has initiated Facebook with a Buy rating, saying that Facebook is in the early stages of monetizing its user base. The firm noted that Facebook’s global penetration is only about 20 percent and that it sees upside from Instagram magnetization and the upcoming launch of the video ad product. The firm’s price target for Facebook shares is $60.
Moody’s (NYSE:MCO): Lazard Capital has raised its price target for Moody’s to $79 from $74, saying that Moody’s new issue pipeline appears to be strengthening. The firm maintained a Buy rating on Moody’s stock.
Jazz Pharmaceuticals (NASDAQ:JAZZ): After attending a Food and Drug Administration meeting on narcolepsy, Cantor Fitzgerald believes that narcolepsy patients have a high awareness and are favorably predisposed to Jazz Pharmaceuticals’s medication Xyrem. The firm reiterates a Buy rating on Jazz Pharmaceuticals’s shares.
Autodesk (NASDAQ:ADSK): Pacific Crest has lowered its Autodesk estimates following a reseller check that indicates there has been little improvement in Autodesk’s business since July, and that there is a lack of reseller understanding of Autodesk’s model transition. The firm rates Autodesk’s shares a Sector Perform and sees downside to $30.
Don’t Miss: Pandora: Bring It On, iTunes Radio